InvestorsHub Logo
Followers 65
Posts 23841
Boards Moderated 0
Alias Born 11/23/2016

Re: OFP post# 126764

Friday, 10/27/2017 11:26:34 AM

Friday, October 27, 2017 11:26:34 AM

Post# of 461289
Inclusion/exclusion criteria based upon KEM analysis extended by DNA/RNA profiling along with gut biome data.

As a PR bonus following CTAD perhaps Part C longitudinal data and update on how the patients are doing now. As extra bonus more concrete information on trial start.

What have I missed or what else could it be?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News